URB597

URB597 (also known as KDS-4103) is a FAAH inhibitor that increases the concentration of anandamide, an endocannabinoid, in the brain. It was developed by the Italian pharmaceutical company Kadmus Pharmaceuticals.

History

URB597 was first synthesized in the early 2000s by a team of researchers at the University of Urbino, Italy. The compound was named after the university's initials and the number of the compound in the series of FAAH inhibitors they were developing.

Pharmacology

URB597 works by inhibiting the fatty acid amide hydrolase (FAAH), an enzyme that breaks down anandamide. By inhibiting FAAH, URB597 increases the levels of anandamide in the brain. Anandamide is a neurotransmitter that is involved in pain, depression, appetite, memory, and fertility. It is also a natural ligand for the cannabinoid receptors.

Clinical Trials

URB597 has undergone Phase I and II clinical trials for the treatment of anxiety disorders and major depressive disorder. However, the development of the drug was discontinued due to lack of efficacy in these trials.

Potential Therapeutic Uses

Despite the discontinuation of its development for anxiety and depression, URB597 has shown potential in preclinical studies for the treatment of various conditions. These include neuropathic pain, inflammatory pain, neurodegenerative diseases, and addiction.

Side Effects

The most common side effects of URB597 include dizziness, nausea, and headache. In rare cases, it can cause hypotension and tachycardia.

Legal Status

URB597 is not currently approved for medical use in any country. However, it is available for research purposes.

See Also

• Cannabinoid
• Endocannabinoid system
• Fatty acid amide hydrolase

This article is a stub related to pharmacology. You can help WikiMD by expanding it!